Regulatory FDA turns to old drugs to address new diseases, persistent medical needs BioSpaceThe FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) BioSpace The FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need. Read full story Post navigation Previous: Novo says high-dose Wegovy can cause 28% weight lossNext: BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
